Latest Period
Q4 2025
Security Snapshot
BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE) Institutional Ownership
CUSIP: 07782B104
13F Institutional Holders and Ownership History from Q2 2022 to Q1 2026
Institutions Reporting
69
Shares (Excl. Options)
7,189,642
Price
$159.96
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Ordinary Shares, par value US$0.0001 per share
- Symbol
- BLTE on Nasdaq
- Shares outstanding
- 37,379,062
- Price per share
- $169.79
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 7,189,642
- Total reported value
- $1,152,680,330
- % of total 13F portfolios
- 0%
- Share change
- +4,872,135
- Value change
- +$809,703,843
- Number of holders
- 69
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- BLTE - BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share is tracked under CUSIP 07782B104.
- 69 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 69 to 13 between Q4 2025 and Q1 2026.
- Reported value moved from $1,152,680,330 to $124,961,260.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 69 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 07782B104?
CUSIP 07782B104 identifies BLTE - BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 07782B104:
Significant Owners of BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 54% | $1,065,034,885 | 17,095,263 | Lin Bioscience International Ltd. | 31 Dec 2024 | |||
| Darwin Global Management, Ltd. | 8.1% | +16% | $479,467,205 | +$65,024,200 | 3,027,704 | +16% | Darwin Global Management, Ltd. | 31 Dec 2025 |
| Lin Yu-Hsin | 7.1% | $142,484,461 | 2,287,070 | Yu-Hsin Lin | 31 Dec 2024 |
As of 31 Dec 2025, 69 institutional investors reported holding 7,189,642 shares of BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE). This represents 19% of the company’s total 37,379,062 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE) together control 19% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 8.1% | 3,027,704 | 9.9% | $486,915,357 | |
| RTW INVESTMENTS, LP | 1.9% | 715,332 | +129% | 1.1% | $114,424,507 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 558,882 | +2595% | 0.06% | $89,398,765 |
| RA CAPITAL MANAGEMENT, L.P. | 1.2% | 432,484 | -51% | 0.71% | $69,180,141 |
| PERCEPTIVE ADVISORS LLC | 1.1% | 414,239 | +732% | 1.2% | $66,261,670 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1% | 383,091 | +96% | 0.96% | $61,279,236 |
| Point72 Asset Management, L.P. | 0.76% | 284,437 | +9075% | 0.07% | $45,498,543 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0.63% | 233,813 | 0.48% | $37,400,727 | |
| MARSHALL WACE, LLP | 0.52% | 192,700 | +2.8% | 0.03% | $30,824,292 |
| UBS Group AG | 0.34% | 128,752 | +1036% | 0% | $20,595,170 |
| MPM BIOIMPACT LLC | 0.23% | 87,760 | 1.6% | $14,038,090 | |
| Holocene Advisors, LP | 0.22% | 84,067 | 0.03% | $13,447,357 | |
| FRED ALGER MANAGEMENT, LLC | 0.21% | 79,394 | 0.05% | $12,699,864 | |
| Western Standard LLC | 0.16% | 60,026 | 4.4% | $9,601,759 | |
| GOLDMAN SACHS GROUP INC | 0.12% | 44,599 | +1103% | 0% | $7,134,056 |
| Soleus Capital Management, L.P. | 0.11% | 40,354 | -81% | 0.27% | $6,455,026 |
| ADAR1 Capital Management, LLC | 0.11% | 39,839 | 0.48% | $6,372,646 | |
| JANE STREET GROUP, LLC | 0.09% | 32,318 | 0.01% | $5,169,587 | |
| MORGAN STANLEY | 0.07% | 28,013 | +436% | 0% | $4,480,960 |
| Squadron Capital Management LLC | 0.07% | 26,000 | 0% | 1.9% | $4,158,960 |
| Quadrature Capital Ltd | 0.07% | 24,832 | +548% | 0.04% | $3,972,127 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.07% | 24,703 | 2.1% | $3,951,492 | |
| Affinity Asset Advisors, LLC | 0.05% | 20,000 | 0.23% | $3,199,200 | |
| PFM Health Sciences, LP | 0.05% | 19,823 | 0.32% | $3,170,887 | |
| Woodline Partners LP | 0.05% | 18,041 | 0.01% | $2,885,838 |
Institutional Holders of BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 783,751 | $124,961,260 | +$91,099,962 | $159.44 | 13 |
| 2025 Q4 | 7,189,642 | $1,152,680,330 | +$809,703,843 | $159.96 | 69 |
| 2025 Q3 | 2,288,469 | $169,346,585 | +$162,953,207 | $74.00 | 34 |
| 2025 Q2 | 78,139 | $4,508,619 | -$5,101,966 | $57.70 | 18 |
| 2025 Q1 | 149,657 | $9,909,658 | -$8,038,751 | $66.22 | 18 |
| 2024 Q4 | 282,406 | $17,820,740 | +$12,809,959 | $63.10 | 21 |
| 2024 Q3 | 78,699 | $3,689,407 | -$4,872,726 | $46.88 | 15 |
| 2024 Q2 | 186,568 | $8,522,342 | +$5,980,161 | $45.68 | 11 |
| 2024 Q1 | 58,112 | $2,229,758 | -$4,083,463 | $38.37 | 11 |
| 2023 Q4 | 155,109 | $7,095,600 | +$3,531,143 | $45.75 | 17 |
| 2023 Q3 | 99,593 | $3,165,868 | -$26,250,075 | $31.85 | 7 |
| 2023 Q2 | 1,040,502 | $14,866,363 | +$2,374,158 | $14.29 | 6 |
| 2023 Q1 | 850,185 | $25,389,513 | -$211,069 | $29.90 | 8 |
| 2022 Q4 | 857,329 | $25,861,711 | +$22,306,675 | $30.15 | 7 |
| 2022 Q3 | 115,088 | $3,870,578 | +$1,586,624 | $33.76 | 8 |
| 2022 Q2 | 68,935 | $2,146,000 | +$2,146,000 | $31.13 | 6 |